吉西他滨膀胱灌注治疗非肌层浸润性膀胱癌的疗效及血清VEGF的影响

doi:10.3969/j.issn.1009-976X.2021.04.014

摘要/Abstract

摘要： 目的为探究吉西他滨（GEM）膀胱灌注治疗在经尿道膀胱肿瘤电切术（TURBt）后的非肌层浸润性膀胱癌（NMIBC）患者的临床效果以及对血清VEGF的影响。方法回顾性选取2015年1月~2019年6月在玉溪市人民医院接受TURBt治疗的132例NMIBC患者为研究对象,将患者分为GEM组和吡柔比星组（THP组）,每组均为66例。两组均行TURBt治疗,GEM组术后立即采取GEM膀胱灌注,THP组术后立即采取THP膀胱灌注。通过对比两组术后灌注治疗过程中的不良反应,并随访1年,监测两组术后0.5年、1年的复发情形;分别在灌注前、灌注后0.5年及1年抽取4 mL空腹静脉血,检测血清VEGF的水平。结果 GEM组灌注后0.5年、1年复发率低于THP组,复发时间长于THP组,具有统计学意义（P<0.05）;两组灌注后0.5年、1年血清VEGF水平均低于灌注前,两组灌注后1年血清VEGF水平与灌注后0.5年水平相比,处于一个降低的趋势,但GEM组患者灌注后0.5年、1年血清VEGF均明显低于THP组,下降的趋势更大,差异有统计学意义（P<0.05）。结论 GEM膀胱灌注治疗在NMIBC病人行TURBt后取得的临床效果较好。

关键词: 吉西他滨, 吡柔比星, 非肌层浸润型膀胱癌, 血清VEGF

Abstract: Objective To explore the clinical effect of Gemcitabine （GEM） bladder perfusion therapy in patients with non-muscular invasive bladder cancer （NMIBC） after transurethral resection of bladder tumor （TURBt） and its influence on serum VEGF. Methods 132 patients with NMIBC who were treated with TURBt in Yuxi People's Hospital from January 2015 to June 2019 were included in this study. The patients were randomly divided into GEM group and Pirarubicin group （Pirarubicin, THP group）, with 66 patients in each group. Both groups were treated with TURBt. The GEM group received GEM bladder perfusion immediately after the operation, and the THP group received THP bladder perfusion immediately after the operation. By comparing the adverse reactions of the two groups during postoperative perfusion treatment, and followed up for 1 year, the recurrence of the two groups was monitored 0.5 years and 1 year after the operation. 4ml fasting venous blood was drawn before the perfusion, 0.5 years and 1 year after the perfusion, respectively, to detect the level of serum VEGF. Results The recurrence rate of the GEM group was lower than that of the THP group at 0.5 and 1 year after perfusion, and the recurrence time was longer than that of the THP group, which was statistically significant （P<0.05）; the serum VEGF levels of the two groups were lower than before the 0.5 year and 1 year after perfusion. The serum VEGF levels of the two groups at 1 year after perfusion were in a decreasing trend compared with 0.5 years after perfusion. However, the serum VEGF levels in the GEM group were significantly lower than those in the THP group at 0.5 and 1 year after perfusion, and the downward trend was greater and the difference was greater （P<0.05）. Conclusion GEM bladder perfusion therapy has achieved better clinical effects after TURBt in NMIBC patients, and has a significant effect on serum VEGF. It can not only effectively prevent and significantly reduce the recurrence rate of patients after surgery, but also improve the recurrence-free survival rate. It has less toxic side effects and causes adverse effects the response is less, which is more conducive to ensuring the prognosis and recovery of patients, and has high clinical application value. It is worthy of vigorous research in clinical treatment, strive for widespread application, and provide patients with appropriate treatment options.

Key words: gemcitabine, Pirarubicin, non-muscular infiltrating bladder cancer, serum VEGF

中图分类号:

R737.14

王龙, 王健, 佟发春, 翟成喜, 刘昀瓒, 邓仁强, 王彬. 吉西他滨膀胱灌注治疗非肌层浸润性膀胱癌的疗效及血清VEGF的影响[J]. 岭南现代临床外科, 2021, 21(04): 441-444.

WANG Long, WANG Jian, TONG Fa-chun, ZHAI Cheng-xi, LIU Yun-zan, DENG Ren-qiang, WANG Bin. Efficacy of gemcitabine bladder perfusion in the treatment of non-muscular invasive bladder cancer and the effect of serum VEGF[J]. Lingnan Modern Clinics In Surgery, 2021, 21(04): 441-444.

参考文献

[1] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] Soloway MS, Sofer M, Vaidya A.Contemporary management of stage T1 transitional cell carcinoma of the bladder[J]. J Urol
2002, 167(4): 1573-1583.
[3] Cheng L, Weaver AL, Neumann RM, et al.Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: A new proposal[J]. Cancer, 1999, 86(6): 1035-1043.
[4] Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer[J]. J Urol, 1992, 147(3): 596-600.
[5] van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy[J]. Eur Urol, 2009, 56(3): 430-442.
[6] 邓海清,张孝斌,程帆. 膀胱灌注卡介苗治疗非肌层浸润性膀胱癌的研究进展[J]. 现代泌尿生殖肿瘤杂志, 2016, 8(5): 309-312.
[7] Huang B, Huang G, Li W, et al.Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor[J]. J Cancer Res Clin Oncol, 2020, 147(6):1781-1788.
[8] Jiang B, Dong Y, He H, et al.Application of pirarubicin photosensitizer fluorescence cystoscopy in early detection of bladder cancer[J]. Oncol Lett, 2017, 14(3): 3309-3312.
[9] 王斌,宋继文,陈惠庆,等. 术前及术后膀胱灌注与单纯术后膀胱灌注吡柔比星预防非肌层浸润性膀胱癌术后复发的前瞻性随机对照研究[J]. 肿瘤研究与临床, 2017, 29(3): 155-159.
[10] 张建武,李云祥,刘文虎,等. PI3K抑制剂LY294002联合吡柔比星对膀胱癌BIU-87细胞增殖作用的影响[J]. 川北医学院学报, 2017, 32(2): 189-192.
[11] Hensley ML, Maki R, Venkatraman E, et al.Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial[J]. J Clin Oncol, 2002, 20(12): 2824-2831.
[12] Pestieau SR, Stuart OA, Chang D, et al.Pharmacokinetics of intraperitoneal gemcitabine in a rat model[J]. Tumori, 1998, 84(6): 706-711.
[13] Abbruzzese JL, Grunewald R, Weeks EA, et al.A phase I clinical, plasma, and cellular pharmacology study of gemcitabine[J]. J Clin Oncol, 1991, 9(3): 491-498.
[14] 刘志飞,邢力永,邓刚,等. 核糖核苷还原酶M1在膀胱癌中的表达及其与吉西他滨药物疗效的关系[J]. 中华实验外科杂志, 2018, 35(3): 597.
[15] Huang P, Chubb S, Hertel LW, et al.Action of 2′,2′-difluorodeoxycytidine on DNA synthesis[J]. Cancer Res,1991, 51(22): 6110-6117.
[16] 董自强,胡敬祖,易明,等. 吉西他滨与羟基喜树碱对非肌层浸润性膀胱癌灌注化疗效果的回顾分析[J]. 现代泌尿生殖肿瘤杂志, 2018, 10(3): 140-144.
[17] Laufer M, Ramalingam S, Schoenberg MP, et al.Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study[J]. J Clin Oncol, 2003, 21(4): 697-703.
[18] Liu M, Li H, Wang X, et al.Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer-bearing mice and patients[J]. Cancer Med, 2020, 9(8): 2660-2673.